News

Targeted Oncology5d
FDA Approves Taletrectinib for ROS1-Positive Non-Small Cell Lung Cancer
The FDA approved taletrectinib for ROS1-positive NSCLC. The agent shows efficacy for both new and pretreated cases, including ...
Nuvation Bio granted FDA approval for lung cancer therapy Ibtrozi
Nuvation Bio (NYSE:NUVB) announced on Wednesday that the U.S. Food and Drug Administration (FDA) has approved its oral ...
MedPage Today on MSN6d
Next-Generation TKI Approved for Advanced ROS1-Positive Lung Cancer
The FDA approved taletrectinib (Ibtrozi)-- a next-generation oral ROS1 tyrosine kinase inhibitor (TKI) -- for the treatment ...
Business Wire6d
U.S. Food and Drug Administration Approves Nuvation Bio’s IBTROZI™ (taletrectinib), a Next-Generation Oral Treatment for Advanced ROS1-Positive Non-Small Cell Lun…
Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer ...
Large study finds no significant overall cancer risk increase with JAK inhibitors in RA
Regulatory authorities issued precautionary recommendations following the ORAL Surveillance trial, which demonstrated an ...
BioPharma Dive5d
FDA clears Nuvation lung cancer drug, setting up battle with Bristol Myers and Roche
The drug, Ibtrozi, will now vie for market share in an indication where multiple large pharmaceutical companies have already ...
National Geographic news4d
Why cancer rates are rising in young women—and what to do about it
Also contributing are women’s higher rates of thyroid cancer, and rising rates of cervix and uterus cancers. And while lung cancer rates are decreasing for everyone, they’re declining more ...